KZIA - Kazia Therapeutics Limited
NASDAQ
->
Healthcare
->
Biotechnology
Sydney,
Australia
Type: Equity
KZIA price evolution
KZIA
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Jul 2022 | 30 Mar 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.24 | $4.39 | $7.36 | $7.36 |
| Short term investments | ||||
| Net receivables | $3.9 | $0.74 | $0.09 | $0.05 |
| Inventory | ||||
| Total current assets | $10.77 | $5.92 | $7.61 | $7.61 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $28.09 | $27.84 | $34.96 | $34.96 |
| Current liabilities | ||||
| Accounts payable | $0.86 | $2.31 | $1.52 | $1.52 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.57 | $5.58 | $4.69 | $4.69 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $16.03 | $16.25 | $16.32 | $16.32 |
| Shareholders' equity | ||||
| Retained earnings | -$84.66 | -$77.99 | -$64.99 | -$68.25 |
| Other shareholder equity | -$0.74 | -$0.77 | -$0.85 | $2.41 |
| Total shareholder equity | $18.64 | $18.64 | ||
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 29 Jun 2021 | 29 Jun 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.24 | $7.36 | $27.59 | $8.76 |
| Short term investments | ||||
| Net receivables | $3.9 | $0.09 | $0.08 | $1.19 |
| Inventory | ||||
| Total current assets | $10.77 | $7.61 | $29.39 | $10.65 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $21.44 | $8.33 | ||
| Total investments | ||||
| Total assets | $28.09 | $34.96 | $58.09 | $23.06 |
| Current liabilities | ||||
| Accounts payable | $0.86 | $1.52 | $1.89 | $1.69 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.57 | $4.69 | $8.33 | $5.07 |
| Long term debt | ||||
| Total noncurrent liabilities | $8.9 | $2.6 | ||
| Total debt | ||||
| Total liabilities | $16.03 | $16.32 | $20.24 | $8.94 |
| Shareholders' equity | ||||
| Retained earnings | -$84.66 | -$64.99 | -$44.2 | -$36.19 |
| Other shareholder equity | -$0.74 | -$0.85 | $1.76 | $1.53 |
| Total shareholder equity | $18.64 | $37.85 | $14.13 | |
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Jul 2022 | 30 Mar 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.02 | $0 | $0 | |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $4.61 | |||
| Selling, general & administrative | $1.19 | |||
| Total operating expenses | $10.51 | $13.64 | $11.6 | $5.8 |
| Operating income | -$5.8 | |||
| Income from continuing operations | ||||
| EBIT | -$5.8 | |||
| Income tax expense | -$0.14 | -$0.14 | -$0.05 | -$0.03 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$6.88 | -$13.59 | -$11.63 | -$5.81 |
| Income (for common shares) | -$5.81 | |||
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 29 Jun 2021 | 29 Jun 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.02 | $0 | $15.18 | $0.99 |
| Cost of revenue | ||||
| Gross Profit | $15.18 | $0.99 | ||
| Operating activities | ||||
| Research & development | $14.54 | $9.49 | ||
| Selling, general & administrative | $7.02 | $3.69 | ||
| Total operating expenses | $24.15 | $24.88 | $21.56 | $13.18 |
| Operating income | -$6.38 | -$12.19 | ||
| Income from continuing operations | ||||
| EBIT | -$6.38 | -$12.19 | ||
| Income tax expense | -$0.27 | -$0.37 | -$0.48 | -$0.3 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$20.47 | -$24.65 | -$8.42 | -$12.47 |
| Income (for common shares) | -$8.42 | -$12.47 | ||
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Jul 2022 | 30 Mar 2022 |
|---|---|---|---|---|
| Net income | -$5.81 | |||
| Operating activities | ||||
| Depreciation | $0.49 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$5.69 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$2.36 | -$0.39 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $12.97 | $5.85 | $3.73 | $1.85 |
| Effect of exchange rate | $0.06 | -$0.02 | $1.18 | $0.31 |
| Change in cash and equivalents | -$2.12 | -$2.97 | -$20.23 | -$3.91 |
| (in millions $) | 30 Jul 2023 | 30 Jul 2022 | 29 Jun 2021 | 29 Jun 2020 |
|---|---|---|---|---|
| Net income | -$8.42 | -$12.47 | ||
| Operating activities | ||||
| Depreciation | $1.27 | $1.08 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$9.11 | -$8.81 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$2.36 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $12.97 | $3.73 | $28.11 | $12.14 |
| Effect of exchange rate | $0.06 | $1.18 | -$0.18 | -$0.18 |
| Change in cash and equivalents | -$2.12 | -$20.23 | $18.82 | $3.33 |
News
Fundamentals
| Market cap | $8.46M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 24.18M |
| Revenue | $22.67K |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$37.90M |
| Revenue Q/Q | 348.40% |
| Revenue Y/Y | -99.85% |
| P/E ratio | -0.22 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 373.28 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.22 |
| EPS | -$1.57 |
|---|---|
| ROA | -120.48% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.42 |
| Quick ratio | N/A |